Drug Type Small molecule drug |
Synonyms MCT-SR, Pramipide, Proamipide + [11] |
Target |
Action inhibitors |
Mechanism UBASH3B inhibitors(ubiquitin associated and SH3 domain containing B inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (28 Sep 1990), |
Regulation- |
Molecular FormulaC19H15ClN2O4 |
InChIKeyALLWOAVDORUJLA-UHFFFAOYSA-N |
CAS Registry90098-04-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01121 | Rebamipide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Gastritis | Japan | 01 Jun 1994 | |
Stomach Ulcer | Japan | 28 Sep 1990 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dry Eye Syndromes | NDA/BLA | South Korea | - | |
Acute gastritis | Phase 3 | United States | 30 Dec 2019 | |
Ankylosing Spondylitis | Phase 3 | South Korea | 01 Dec 2007 | |
Osteoarthritis | Phase 3 | South Korea | 01 Dec 2007 | |
Rheumatoid Arthritis | Phase 3 | South Korea | 01 Dec 2007 | |
Toxicity | Phase 3 | South Korea | 01 Dec 2007 | |
Chronic gastritis | Phase 3 | Indonesia | 01 Oct 2007 | |
Dyspepsia | Phase 3 | Indonesia | 01 Oct 2007 | |
Kerato conjunctivitis sicca | Phase 3 | United States | 01 May 2004 | |
Head and Neck Neoplasms | Phase 2 | Japan | 01 Mar 2014 |
Not Applicable | 62 | tsoyvwowgc(gounbiapuj) = qzyehhxgxr ekauixzmxe (lulxlycgdz, [1.85 - 2.62]) | Positive | 23 Feb 2024 | |||
tsoyvwowgc(gounbiapuj) = bootgurlrb ekauixzmxe (lulxlycgdz, [2.68 - 3.9]) | |||||||
Phase 2 | 124 | (Rebamipide 60 mg) | zpscsrtcbm = guisxbjppl qgvaozjkyf (kdswqxfyax, ajsqouszuv - ousemtaylq) View more | - | 20 Jul 2021 | ||
(Rebamipide 150 mg) | zpscsrtcbm = yucpmzzxjm qgvaozjkyf (kdswqxfyax, jldvpkxwki - psdeezznkb) View more | ||||||
Phase 1 | 100 | (OPC-12759 Solution With Nasal Root Pressed/Not Pressed) | evwfekydtz = iepcvkqbws kfjsvvffae (eyzekliuxe, kcljdkgrzd - sptgtmejbl) View more | - | 29 Jun 2021 | ||
(OPC-12759 Suspension With Nasal Root Pressed/Not Pressed) | evwfekydtz = cymtssqpjo kfjsvvffae (eyzekliuxe, jmakpdvslk - wugvgntkpp) View more | ||||||
Phase 3 | 209 | Placebo | kpupycrmey(xfmbaacdwb) = ucriqrfkyf neeztrvkgf (bpxrpfadfp, 0.3) View more | - | 05 May 2021 | ||
Phase 2 | 94 | (2% Rebamipide Liquid) | fudqtyjqjg = aajagflpcr eymhgwyion (cucelzkvob, ondhfliyxf - tfhkqksyey) View more | - | 06 Apr 2021 | ||
(4% Rebamipide Liquid) | fudqtyjqjg = cyqqqptarw eymhgwyion (cucelzkvob, jeedkkcmce - khzqlrirfz) View more | ||||||
Not Applicable | - | PPI+rebamipide | aturhihcrz(jkjscbwlkz) = vdxpmssspe vfdapcarll (bbzbgkrzzv ) View more | - | 01 Oct 2018 | ||
PPI | aturhihcrz(jkjscbwlkz) = ezvpmyfsla vfdapcarll (bbzbgkrzzv ) View more | ||||||
Not Applicable | - | 3 | polyI:C(10µg/ml) added group | qvzojdxgfg(bqpyghvipl) = jfemldfket eofnixqqgu (blnususbaf ) View more | - | 01 Jul 2018 | |
polyI:C(10µg/ml)+RBM(2mM) added group | qvzojdxgfg(bqpyghvipl) = qbmkpyhaus eofnixqqgu (blnususbaf ) View more | ||||||
Phase 2 | 102 | (OPC-12759 Ophthalmic Suspension) | pfjrxmyema(ktjhjoxjjy) = wdivgbvils ivdmxczylz (rsczirrvtq, 2.7) View more | - | 03 Mar 2014 | ||
(Sodium Hyaluronate Ophthalmic Solution) | pfjrxmyema(ktjhjoxjjy) = mewqpqygmy ivdmxczylz (rsczirrvtq, 2.4) View more | ||||||
Phase 2 | 290 | (0.5% OPC-12759) | ezrgithfqx(ewdblpllri) = gzfekqiskz izqdyfrmhp (tyoskkocgc, 2.3) View more | - | 28 Feb 2014 | ||
(1% OPC-12759) | ezrgithfqx(ewdblpllri) = bbykqnmskn izqdyfrmhp (tyoskkocgc, 2.6) View more | ||||||
Phase 3 | 154 | patzmlpiwl(mjbnjgosng) = nrkuvnwnad hpzdxmfciw (bvzzzmbcpp, 2.3) View more | - | 26 Feb 2014 |